| This site is
regularly updated with articles, surveys and reports and analyses
relevant to our clients, investors, the biotechnology industry,
as well as life sciences and commercialisation issues.
Innovation Dynamics regularly holds BioBusiness Forums (BBFs) and CEO Dinners to discuss and canvass issues of concern to the life sciences sector. BBFs are held in Sydney and are public events, details of which are provided on this page and are emailed to those that wish to be contacted when a Forum is pending. If you wish to be added to the mail list for BBFs please contact us.
CEO Dinners are held occasionally in capital cities other than Sydney and are by invitation only. They are only open to CEOs of life sciences companies. If you want more information please contact us.
Innovation Dynamics bade farewell to longstanding industry adviser Tony Coulepis at the end of June to enable Tony to pursue his other interests. Tony has been with Innovation Dynamics since June 2005 after moving back into industry from his former position as the CEO of AusBiotech. Tony has developed a diverse portfolio of other business interests, which he will be expanding. Tony has built Innovation Dynamics' client base in Victoria very effectively and remains a close friend of the company. Innovation Dynamics will be commencing recruitment to replace Tony and build on the foundations developed to establish an increased presence for Innovation Dynamics in Melbourne.
May is turning out to be conference month with four Innovation Dynamics' staff presenting at national and international conferences during the month.
- Come and see our display & meet the Head of Business Development Services, Mr John Grew at AusMedtech 08 on 13 – 15 May in Sydney. For more information and registration click on this link - AusMedtech 08
- Dr Kelvin Hopper & Mr John Grew, will be presenting at a workshop in Canberra, Building a Framework Around Commercialising Your Unique IP to Maximise Organisational Outcomes on 16 May at the “IP Governance & Knowledge Commercialisation Conference 2008”, click on link for more information and registration.
- Dr Tony Coulepis is speaking on Driving Continuous Innovation in your Organisation at the Case Studies on IP Management in Sydney 19 – 21 May, click on link for more information and registration. He is also running a workshop on IP Metrics & Analytics - IP as a more Strategic Part of the Business on 21 May at the same conference
- Dr Lyndal Thorburn is speaking on The Impact of Innovation Policies in Regional Development: the Australian experience at a Chilean government sponsored conference on National Science Policies for Regional Innovation in regional Chile on 20 – 22 May. Dr Thorburn has been invited as one of a group of international speakers, the others coming from the US. The local organisers are Idea Consultora
- Dr Lyndal Thorburn is speaking on Best Practice in Science-Industry Research Linkages in Australia at a conference on IP Metrics and Technology Transfer in Santiago, Chile on 28 and 29 May. Dr Thorburn, together with speakers from Stanford and Florida State Universities in the US and Rio Grande del Sud Uni in Brazil, will present case studies from around the world and will participate in panel sessions with local policy makers and R&D institutions. The local organisers are NEOS Tecnologica
Innovation Dynamics' Chairman, Dr Kelvin Hopper, presented an overview of the Australian and New Zealand biotech scene at the "Excellence in Biotechnology Investment" conference on 21st April in Sydney. Despite restricted funding and low share prices, the potential for future investment in a number of companies is exceptionally good and the biotech sector is robust.
Click here to see full presentation.
Innovation Dynamics is part of the industry exhibition at the forthcoming NZBIO 2008 conference in Auckland, 31 March to 2 April 2008. Come and see us at stand 41 throughout the conference.
The Australian and New Zealand biotechnology companies are performing surprisingly well, despite low share prices, poor media interest and funding difficulties, according to a recent report by Innovation Dynamics Pty Ltd.
The study focused on companies’ underlying operational performance indicators and the full results will be published in the seventh edition of the BioIndustry Review – Australia and New Zealand, to be launched on 21 February 2008.
The data and the analysis reveal that a number of major biotechnology and medical devices companies will complete pre-market clinical trials in the next couple of years and launch new products. In addition, the study found that the number of companies involved in clinical trials increased 40% over the 12 month period, with over half of these companies entering into later stage, phase II or III trials.
Click here for the full press release
You can also order the BioIndustry Review by visiting www.bioindustryreview.com.au or click here for the order form
2007 was a turbulent year for investors and, according to the lack of media interest, the life science sector appeared mostly unloved. Fundraising was especially difficult for the smaller companies and across the board share prices and market capitalisation decreased throughout the year. However some companies, especially CSL and those companies in late stage product development showed an increase in value and were favoured over platform and tool box companies. These major life science companies appear to be meeting their milestones and there has been an unprecedented growth in clinical trials with real prospects for some products reaching the market in 2009. Twenty one new biotech firms were formed in FY2007 and some $161m was raised by nine new biotech IPO’s.
We will discuss the trends in the industry over the past few years and look at the present environment for biotech with particular perspectives on fundraising, business models and the life science company life cycle.
Our guest speaker for the evening is Mr Graeme Kaufman.
Mr Graeme Kaufman: Chief Investment Officer, Strategic Life Sciences Limited .Graeme was formerly with CSL in a variety of positions in research, manufacturing and corporate over a period of 35 years. He was Finance Director at the time of the public float of CSL in 1994 and was one of the major drivers of that process. In 1999 he joined Circadian Technologies as an executive director and took up positions on several subsidiary boards. He was involved in the original concept and establishment of the new investment fund, Strategic Life Sciences, which he joined full time as Chief Investment Officer in November 2007. SLS is a new Melbourne and San Francisco-based global health and life sciences investment company committed to raise AU$400 million. It will invest in mature, emerging and start-up firms in specialist pharmaceuticals, healthcare services, biotechnology (including medical, agricultural and industrial), diagnostics and medical devices. Graeme has a wealth of experience and knowledge of biotech operations, investment and strategy and will look at the trends in the present crop of offerings and the rationale for a new large fund and its approach to this market.
The 2008 BioIndustry Review: Australia and New Zealand,will also be launched at the forum. Come and meet ID’s skilled and growing team at the event.
Click here for full details and the registration form.
Innovation Dynamics today announced exciting new data revealing that over 450 drugs are in development by Australian biotechnology and pharmaceutical companies, with a significant number of compounds in advanced clinical trials.
These findings have been released in Innovation Dynamics' Australia New Zealand (ANZ) Drug Pipeline database, which is the leading, most comprehensive regional Drug Pipeline database commercially available.
Click here for the full press release
Innovation Dynamics can provide access to the largest capital-raising platform for unlisted companies in Australia. Through ASSOB, Innovation Dynamics will be able to work with life sciences and nanotech companies to assist them raise capital for business expansion or growth.
Dr Lyndal Thorburn, Managing Director of Innovation Dynamics, says "Innovation Dynamics is delighted to be able to further support technology-based companies raise these very important early rounds of equity investment to fund their growth and expansion.".
Click here for full press release
The Australian Securities and Investment Commission (ASIC) has released two new regulatory guidelines for the preparation of expert reports under their Australian Financial Services licensing. These follow a discussion paper "Better Expert Reports" and describe the circumstances when they are mandated, the content of the reports and requirements for the independence of the authors of such reports. Following is a link to the guides.
Innovation Dynamics is licensed to prepare these reports and adheres to these guides. Under some circumstances expert reports are mandatory. At other times they are discretionary and, when they are used, provide investor confidence in the offer.
Content of Expert Reports
Independence of experts
Innovation Dynamics is delighted to announce that it has been appointed specialist adviser to newly formed Strategic Life Sciences Limited (SLS) which was launched on 9 November 2007. SLS is a new Melbourne and San Francisco based global health and life sciences investment company. SLS is committed to raise AU$400 million to invest in mature, emerging and startup life sciences companies. Innovation Dynamics has a preferred supplier relationship to provide advice to SLS on industry trends, potential areas for investment, valuations and specific investment opportunities. Innovation Dynamics will also advise SLS on convergence opportunities for life sciences in industrials, new materials and nanotechnology.
Was held on Thursday 8th November, 2007.
Three prominent speakers were:
Stephen Carroll, General Manager of Orica Advanced Water Technologies.
David Garman, CEO of the Environmental Biotechnology CRC .
Andrew Doig, Director of the Australian Environment Business Network (AEBN).
International corporate advisory company, Innovation Dynamics Pty Ltd has appointed Mr John D Grew MSc MBA as head of its Sydney office.
Mr grew has a successful senior management career within the biopharmaceutical, life science and agribusiness industries, having worked previously for CSR Ltd, Progen Industries Ltd and more recently, Fort Dodge Animal Health (Australia) Pty Ltd. He has extensive business development and technical skills in highly regulated industries as well as proven process improvement and business building experience within established global corporations and start-up high technology companies.
Click here for full Press Release
Innovation Dynamics has just released its 2006-07 annual report covering its third year of operations since it was formed from the merger of Aoris Nova Pty Ltd and Advance Consulting & Evaluation Pty Ltd. The company has formalised its internal structure and has continued its move into export markets.
Click here to download
Innovation Dynamics continues its support for Australian industry this month through finalisation of a business case for a COMET-funded company and ongoing work in market entry strategy for a US firm which has set up an Australian subsidiary. Innovation Dynamics is also working closely with a listed public company to identify potential funding sources for a major infrastructure initiative.
A new report on biotechnology grants available from the EU & US Governments, US philanthropic foundations, public/private partnerships and supranational government funded entities is now available.
Available in Australia through Innovation Dynamics Pty Ltd, the 123 page report provides:
- Comprehensive background information on each fund including contact details
- Value and size of the fund
- Key focus of each fund
- Information to assist in development of the applications
Profiles of each grant entity are coded to clarify the research and development financed by each fund for example:
- Fundamental research e.g. molecular basis of juvenile diabetes
- Clinical trial research
- Research and technology in the farming or environmental science sector
- Education, health & wellbeing programs
Click here for more detail and to order
Innovation Dynamics announced today the launch of its New Zealand supplement to its existing Australian Drugs-in-Development Pipeline database. The New Zealand supplement contains information on 135 drugs in
development across research institutes, universities and companies in New Zealand.
The entire Australia-New Zealand database now contains over 300 drugs and vaccines in over 155 organisations from preclinical development to Phase 3. In addition the company’s Drugs-In-Development Pipeline database includes information on over 250 drugs and vaccines in discovery or early stage research.
Click here for more detail
Australian scientists are recognised for world class innovation but historically the challenge has been translating that work into commercial success. Making connections to companies and markets overseas is critically important to this process.
Two Australians in leading life sciences companies have been given a unique opportunity to build their networks within the global arena as the result of an important initiative from Merck Sharp & Dohme and Advance – the Advancing BioBusiness Award. This Award, which aims to build commercialisation capability, enabled the two scientists to attend BIO 2007, as well as participate in a tailored program of meetings with leading organisations involved in the life sciences sector, organised through Advance's extensive global network.
Sharing their experiences as the 2007 winners of the Advancing BioBusiness Award will be:
John Lambert is the Executive Director, Drug Discovery, Biota Holdings Ltd. In this role, he is responsible for the collaborative management of the company's IP portfolio, assisting drug discovery teams in determining directions and priorities and managing technical interactions with strategic partners.
Andrew Wilks is the Chief Scientific Officer for Cytopia, which has grown from its origins in Andrew's lab at the Ludwig Institute for Cancer Research to become an ASX-listed company which is seeking new drugs for cancer, immune disease and cardiovascular disease, with a focus on kinases as drug targets.
We'll also have members of the two partner organisations, Merck Sharp & Dohme and Advance:
Will Delaat is the Managing Director of Merck Sharp & Dohme Australia (MSD), the Australian subsidiary of the global research-based pharmaceutical company Merck & Co Inc. Since 1995, MSD has brought more than 20 new medicines to Australians and provides ongoing support of innovative research and science in Australia. Mr Delaat is also Chair of the Pharmaceuticals Industry Council, which brings together the innovative, generic and biotechnology industries to represent a whole-of-sector approach to investment in the sector.
Ken Allen is the Chairman Emeritus of Advance. Prior to his current appointment as Senior Advisor, Asia Pacific for UBS Invest Bank, Ken was the Australian Consul General in New York until February 2006. Advance is a not-for profit organisation which links Australian professionals who are working and living overseas. Its global life sciences network features over 1000 professionals in more than 100 pharmaceutical companies, research institutes and service providers, to provide Australian organizations and individuals with invaluable global networks of influence.
Was held on Monday 20th August, 2007
Innovation dynamics is working on a number of significant projects this month including a valuation for an expected future ASX listing by a company in Brisbane, a business plan for a Melbourne-based CRC and a Commercial Ready grant application for a Sydney-based group. The company is also finishing a major report on biotechnology in agriculture for the Department of Agriculture Fisheries and Forestry.
Innovation Dynamics is finalising a major research project for Invest Australia this month as well as its role in a major report on GM Canola for the Department of Agriculture Fisheries and Forestry. The company also finished a major industry development strategy for the Queensland government.
Was held on Thursday 26th April, 2007.
Two prominent speakers were:
Mr Denis Hanley , Chairman: Pharmaxis Ltd, CathRx Ltd and Lochard Ltd.
Mr Bob Moses , Chairman: TGR BioSciences Pty Ltd, Antisense Therapeutics Ltd and Sylvan Scientific Ltd.
Employment in the Australian biotech sector has doubled over the last two years according to an industry survey, conducted by Innovation Dynamics Pty Ltd, that will be published in the 2007 BioIndustry Review - Australia and New Zealand on 27th February 2007.
The survey data showed that Australian-based employment in core biotech firms grew from 6,100 employees in late 2004 to at least 12,100 employees in late 2006.
Click here for more details.
Sydney, Australia: 1 February 2007: Innovation Dynamics Pty Ltd today announced the results of new analysis indicating that a growing number of Australian biotechnology companies are attracting international attention.
The new data will be published later this month in the 2007 BioIndustry Review - Australia and New Zealand, an authoritative source of information on the Australasian biotech sector written and published annually by Dr Kelvin Hopper and Dr Lyndal Thorburn of Innovation Dynamics Pty Ltd.
Click here for more details.
Was held on Thursday 27th February, 2007.
Two prominent speakers were:
Alison Coutts: Founder and Executive Director of EG Capital.
Mike Quinn: Founder and CEO of Innovation Capital.
. Mark Mitchell, Virtuocity
. Chris Blaxland, Hunter Partners, LLC (USA)
. Sergio Grdovic, Korean Trade-Investment Promotion Agency
Thanks to a new agreement between Innovation Dynamics Pty Ltd and Microsoft reseller GrapeCity Australia Pty Ltd, pharmaceutical manufacturers will now have enterprise management software available that is specifically tailored to their needs as Good Manufacturing Practice (GMP) manufacturers.
Click here for more information.
ASX listed companies now have access to a powerful turn-key solution that will allow them to achieve best practice in corporate governance, risk management and compliance.
The Novation corporate governance tool is an online software application that will enable ASX listed biotechnology and medical devices companies to quickly and cost effectively satisfy their extensive risk management and compliance obligations.
Click here for more information.
Innovation Dynamics Pty Ltd has just been anointed the 2006 Emerging Exporter at the 2006 ACT Chief Minister's Export Awards in Canberra. This award is given for outstanding export achievement by an enterprise in any industry sector which has been exporting goods or service for 3 yrs or less.
The Managing Director of Innovation Dynamics, Dr Lyndal Thorburn, accepted the award on behalf of the company at the presentations, held during ACT Focus on Business week.
Click here for more information.
Innovation Dynamics announced today the formation of a strategic alliance with NEOS Technologica & Mercado, located in Santiago, Chile. The Alliance opens up business opportunities for Australian and South American companies.
Under the terms of the strategic agreement, Innovation Dynamics (ID) and NEOS will identify strategic and collaborative opportunities for South American and Australian companies seeking to explore business, alliance and market opportunities in Australasia and South America, and will assist with the expansion of companies into these territories.
Click here for more information.
Innovation Dynamics announced today the formation of a strategic alliance with the Biotechnology Center of Excellence, located in Boston, Mass., USA.
The new alliance opens up additional opportunities between Australia and the US in life sciences and biotechnology, as both organisations are closely involved in this sector in their home markets.
Click here for more information.
Innovation Dynamics announced today the formation of a strategic alliance with Kensington Global Alliances LLC, of Chapel Hill, North Carolina in the United States of America.
Kensington Global (KGA) is a licensing, management and business development firm that promotes international alliances. The company operates a global network of industry experts, and has business development operations in Research Triangle Park, North Carolina, U.S.; Basel, Switzerland; Freiburg, Germany; and Auckland, New Zealand.
Click here for more information.
Innovation Dynamics announced today that it has agreed with MyIP (UK) to act on its behalf in Australia to promote and sell MyIP software.
MyIP is innovative software that helps R&D institutions and technology-based companies to manage all aspects of intellectual property management and commercialisation.
Click here to view the press release.
Innovation Dynamics has been awarded a contract from the Department of Agriculture, Fisheries & Forestry to evaluate the contribution of non-GM Biotechnology to Australian agriculture. R&D institutions have been approached to contribute projects.
R&D institutions & companies are welcome to contribute projects to the database, which is open until the end of August. Project details which are received by end of May will be considered for a small number of case studies which will form part of the final report. If you wish to contribute a project please contact us for the survey link.
Innovation Dynamics has been commissioned by the WA Department of Health to advise an appropriate framework for a health R & D strategy for the state. Public submissions have been called in an advertisement in “The West Australian” on 29 April 2006. Submissions must be received by 31 May 2006, in order to be guaranteed consideration in the final report & recommendations. Click here for the Terms of reference.
If you have further queries regarding the submission process, please call either, Ms Miranda Bailey (02) 9209 4235, Mr Jaya Pillai (02) 6295 2190 or Mr Babu Simon, WA Department of Health (08) 9222 2450.
This two volume report was written by ACIL Tasman and Innovation Dynamics after a successful response to a tender from the Department of Industry Tourism and Resources in 2005. The report was presented on 21 February 2006 to the OECD Working Party on Biotechnology and was launched nationally on 30 March 2006. The report includes a comprehensive literature reviews as well as discussion of the role of indicators, surveys, case studies and economic modelling in developing mechanisms to measure the economic impact of biotechnology, now and in the future. At the Australian launch Dr Iain Gillespie, Head, OECD Biotechnology Division, said "Biotechnology will become a micro-economic driver to growth similar to what we have seen for information and communications technologies. Australia is one of three countries that have made a significant contribution to international thinking on biotechnology's impact and what it will mean for society and economic development. This report is a substantial first step towards establishing a framework for measurement of biotechnology's broad impact and the OECD congratulates you on this initiative." The Department of Industry Tourism and Resources has called for comments on the proposed methodology by 30 May 2006. Click here to view presentation
Industry expert, Dr David Capes, has been engaged to commence Innovation Dynamics' operations in Western AustraliaClick here to view press release (31Kb)
The New Zealand biotech sector appears to be shifting towards therapeutics and away from agriculture, according to the newly launched 2006 BioIndustry Review – Australia and New Zealand, and there is growing evidence that the New Zealand government is moving more funding of biotech R&D to the healthcare sector. Click here to view press release (64Kb)
Was held on Thursday 8th November, 2007.
Three prominent speakers were:
Dr John Chiplin, is the newly appointed CEO of Peptech Limited
Dr Alison Coutts, is a founding Director of eG Capital Limited.
An analysis of underlying value in the biotech sector has revealed that, whilst share market prices fluctuated widely in 2005 (with a collapse followed by recovery), many biotech companies that have listed since 2001, and some older companies, have been performing well.Click here to view press release (64Kb)
At least 84 of the 201 biotech and medical devices companies which received Biotechnology Innovation Fund (BIF) grants have progressed to raise further funds. Click here to view press release (61Kb)
Innovation Dynamics Pty Ltd today announced that the Australian Securities and
Investment Commission (ASIC) has granted the company an Australian Financial
Services (AFS) Licence.Click here to view press release (25Kb)
. Mr David Campbell, Monash Commercial
. Dr Ian Edwards, Ausbiotech Ltd
. Mr Murray Hird, Department of Business, Industry and Resource Development
Click here to view press release (775 kb)
Looks at the highlights of the activities undertaken by the Company since its inception in July 2004 through to June 2005.
Click Here to view (342 kb)
Capitalising on Stem Cells
The potential of stem cells to treat intractable diseases has sparked the imagination of the public and of investors. Although the full commercial use of adult stem cells, and embryo-derived stem cells is likely to occur well into the future, there is high expectation among investors for a worthwhile commercial outcome. However the structure of businesses involving cell based therapies, the revenue models and the ethical and legal issues need exploring and that is the basis of this open discussion forum.
Our expert panel to set the scene are Professor Robert Jansen, Medical Director, Sydney IVF Limited and Dr Dianna DeVore, Chief Operating Officer, Australian Stem Cell Centre
Date: Tuesday, 27 September 2005
Time: 6:30pm Drinks & Canapés, for 7.15pm Dinner
Venue: The University and Schools Club, 60 Phillip Street, Sydney
Click Here to view press release
Click Here
to view press release
The 2005 BioIndustry Review was launched on 24 February 2005.
Order now!
BioIndustry Review Order Form
PDF 78Kb
Click Here for Table of
Contents PDF 22 KB
A New Broom: Where is NSW Support for Science and
Medical Research heading?
An evening with Professor Michael Reid and Launch of the 2005
BioIndustry Review
Date: Thursday, 24 February 2005
Time: 6:30pm Drinks & Canapés, for
7.15pm Dinner
Venue: The Foyer, The Biomedical Building,
The Australian Technology Park 1 Central Avenue, Eveleigh
Booking form and information PDF 125Kb
Biotech: are we starting to believe the substance
or the hype?
The economy is strong. Is this the start of a golden age for
biotech? Is it just rewards for patience and sound investment?
Are we running the risk of boiling over or is it just a lot
of hype?
During the evening we have three influential speakers, who have
looked at the listed market in different ways, to give their
provocative views on the immediate past and into 2005.
Our Provocateurs are:
Mike Vitale:
Professor at the Australian Graduate School of Management (AGSM)
UNSW, who recently authored reports on the biotech industries,
including Commercialising Australian Biotechnology in May 2004
and with David Sparling Australian Biotechnology: Do perceptions
and reality meet? in 2003 www.agsm.edu.au
David Blake:
Director of Blake Industry & Market Analysis Pty Ltd the
publisher of Bioshares, which has been a long-standing independent
source of information and analysis of biotech stocks.
www.bioshares.com.au
Stuart Roberts:
Biotech analyst with Southern Cross Equities Limited and writes
the thought provoking email Southern Cross Equities' Australian
Biotechnology Buzz
www.biotechbuzz.com.au
Tuesday 14 th December 2004
6:30pm Drinks, for 7.00pm Dinner
The University & Schools Club
Booking form PDF 88Kb
Tuesday 26th October
2004
Exporting Technology – Case Studies
Firms are often reluctant to share information on how (or if)
they stumbled on the way to their first (or subsequent) export
contracts. This event will give insight into the exporting experiences
of Australian companies. We will launch a report of six company
case studies by Innovation Dynamics and Austrade. Two guest
speakers will give the inside story on their exporting experiences:
Mr Andrew Macarthur
CEO - Plasvacc Pty Ltd
Dr James Campbell
Vice President of Operations - ChemGenex Pharmaceuticals Ltd
Tuesday 26th October 2004
6:30 for 7pm (3 course dinner & drinks)
The National Press Club
Canberra
ACT business woman, Dr Lyndal Thorburn, was
today named the 2004 Telstra ACT Business Woman of the Year,
out of a field of 17 finalists from around the region.
Dr Thorburn took out the prestigious award for her role as Managing
Director of Advance Consulting and Evaluation (now Innovation
Dynamics Pty Ltd) and was presented with the Award
by Jon Stanhope MLA, ACT Chief Minister and Jenny Young, Head
of Consumer Segment, Telstra Consumer and Marketing and International.
Dr Thorburn commenced Advance Consulting & Evaluation in
1996. In July 2004 the company merged with Aoris Nova Pty Ltd
to become Innovation Dynamics. The business specialises in consulting
to governments on industry policy relating to the development
of technology-based industries. Dr Thorburn and her team have
authored reports for federal and state governments that have
shaped policy towards Australia’s emerging biotech industry.
Dr Thorburn was named the ultimate ACT winner after earlier
winning the Westpac Group Business Owner Award (owners with
a 50 per cent share or more in a business, with responsibility
for key management decision making).
Other leading ACT business women recognised for their business
achievements were:
Maria Storti, Chief Finance Officer, ActewAGL,
winner of the Australian Government Private and Corporate Sector
Award (employees in the private and corporate sectors, or owners
with less than a 50 per cent share of a business);
Ciara Doran, General Manager, Capital Linen Services,
winner of the Hudson Community and Government Award (employees
of government departments, statutory bodies and not-for-profit
organisations); and
Ilea Kerans, Managing Director, Canberra Contract Furniture,
winner of the Panasonic Young Business Women’s Award (women
aged 30 years and under, with any of the above criteria).
Dr Thorburn and all category winners will represent the ACT
at the National Telstra Business Women’s Awards, to be
held in Melbourne on 23 October 2004. Winners will share in
a national prize pool of more than $200,000.
31 August 2004
Explore the motives to change a company’s ownership through
mergers by two business leaders with the experience and motivation
to increase the size of their companies.
02 June 2004
EvoGenix Pty Limited finalised its second round of funding,
with investment of $1.9m by BioFusion Capital Pty Limited
and Start-up Australia Ventures Pty Limited. This investment
will be used by EvoGenix to expand the international marketing
of its technology platform as well as continue its internal
cancer drug program.
28 January 2004
The bizNetClub today launched its 2004 Skills Development Program
including the Foundation Series of afternoon interactive workshops,
and the Pillars of Business Success breakfast seminars. These
workshops and seminars are for entrepreneurs and executives
of new technology companies and established growth businesses.
07 January 2004
The biotechnology industries in Australia and New Zealand are
positioned for strong growth after some difficult value building
over the past few years and the emergence of several companies
with good potential internationally.
Aoris Nova and Advance Consulting & Evaluation have published
their third annual review of the Australian and New Zealand
biotechnology industries. |
